Best Cannabis Stocks for 2026: Navigating a Shifting Market

One of the biggest headlines in the cannabis world this year is the federal government's move to reclassify marijuana. On April 22, 2026, the U.S. Drug Enforcement Administration (DEA), following an order from the acting U.S. attorney general, issued a final order that fundamentally changed the federal regulatory status of marijuana. This order moved FDA-approved marijuana drug products and marijuana subject to qualifying state-issued medical marijuana licenses from Schedule I to Schedule III of the Controlled Substances Act (CSA). This is a monumental step, as Schedule I drugs are considered to have no accepted medical use and a high potential for abuse, while Schedule III drugs acknowledge medical utility and have a lower abuse potential.

What does this mean for investors? For state-licensed medical marijuana operators, this rescheduling opens the door to potential DEA registration and, crucially, could significantly reduce or even remove the punitive effects of Section 280E. Currently, Section 280E prevents cannabis businesses from deducting normal business expenses from their federal taxes, leading to much higher effective tax rates than other industries. Imagine the boost to profitability if these companies can suddenly deduct their everyday costs!

Beyond medical cannabis, there's even more to watch. An expedited administrative hearing began on June 29, 2026, to consider whether marijuana as a whole – not just FDA-approved or state-licensed medical products – should be reclassified to Schedule III. This hearing is expected to conclude by July 15, 2026, and its outcome could have even broader implications for the entire cannabis industry, including adult-use operators. However, it's important to remember that this is not full federal legalization, and recreational cannabis not covered by state medical licenses still remains a Schedule I substance for now.

Multi-State Operators, or MSOs, are the companies directly involved in cultivating, processing, and selling cannabis across various states. They're often seen as the backbone of the U.S. cannabis market. Two prominent MSOs that have shown resilience and growth are Trulieve Cannabis (TCNNF) and Green Thumb Industries (GTBIF).

Trulieve Cannabis (TCNNF) is a leading MSO, particularly strong in the medical marijuana space, operating over 230 dispensaries across nine states. The company reported full-year 2025 revenue of $1.2 billion, maintaining a healthy 60% gross margin. Trulieve also generated a record $273 million in cash flow from operations in 2025. More recently, for the first quarter of 2026, Trulieve reported revenue of $287 million and a gross margin of 59%, with a positive net income of $2 million. The company has already begun applying for DEA registration following the medical marijuana rescheduling, which could be a significant operational advantage.

Green Thumb Industries (GTBIF) is another major player, known for its consumer packaged goods and its chain of approximately 100 RISE dispensaries across 14 states. Green Thumb delivered full-year 2025 revenue of $1.2 billion, a 3.4% increase over the prior year, and reported a GAAP net income of $114.2 million. Their normalized EBITDA (earnings before interest, taxes, depreciation, and amortization) for 2025 was $348.4 million. The company ended 2025 with $274 million in cash, providing strong financial flexibility. Green Thumb's stock saw a notable rebound in late 2025, climbing 44% in the six months leading up to January 2026, driven by optimism around legalization.

Curaleaf Holdings (CURLF), with a market cap of around $1.8 billion, stands as the largest American cannabis company. It boasts an extensive network of over 170 dispensaries across 14 states and has an international presence. While its 2025 net revenue is projected to be around $1.28 billion, slightly down from 2024, the company anticipates an adjusted gross margin of approximately 50%. A key catalyst for Curaleaf, and other MSOs currently traded on OTC markets, is the potential for uplisting to major U.S. exchanges like the NYSE or Nasdaq if broader cannabis reclassification to Schedule III occurs.

If you're looking for a way to invest in the cannabis industry without directly touching the plant, ancillary businesses are your 'picks and shovels' play. These companies provide essential services and products to cannabis growers and retailers, often sidestepping some of the direct regulatory risks. Two notable names in this space are Scotts Miracle-Gro (SMG) and Innovative Industrial Properties (IIPR).

Scotts Miracle-Gro (SMG) is a household name in gardening, but its Hawthorne Gardening segment is a major supplier of hydroponic and cultivation equipment to the cannabis industry. For the second quarter of 2026, Scotts Miracle-Gro reported strong results, with revenue reaching $1.5 billion, a 5% increase year-over-year. Their earnings per share (EPS) for Q2 2026 also saw a healthy jump to $4.53, up 13.3% from the same period in 2025. The company's trailing 12-month revenue, ending March 28, 2026, stood at $3.39 billion, with its fiscal year 2025 annual revenue at $3.41 billion. While Hawthorne's performance is tied to the health of commercial cannabis cultivation, Scotts Miracle-Gro's diversified business and strong balance sheet make it a more stable option for investors interested in the cannabis sector.

Innovative Industrial Properties (IIPR) is a unique player, structured as a real estate investment trust (REIT) that focuses exclusively on acquiring and leasing properties to state-licensed cannabis operators. This model allows investors to gain exposure to the cannabis industry's growth through real estate. For the full year 2025, IIPR reported revenues of $266.0 million. However, the first quarter of 2026 saw a slight dip, with revenues of $69.0 million, a 3.8% decrease year-over-year, primarily due to tenant defaults. Despite this, IIPR remains attractive to income-focused investors, as it paid a quarterly dividend of $1.90 per common share in January 2026. The company's strategy provides capital to cannabis operators while generating revenue from lease agreements, offering a different kind of exposure to the sector.

The medical side of cannabis is where biotechnology companies shine, developing FDA-approved, cannabis-derived pharmaceuticals. These companies are less exposed to the direct regulatory hurdles of recreational cannabis and benefit directly from the federal rescheduling of medical marijuana.

Jazz Pharmaceuticals (JAZZ) is a prime example. While not a pure-play cannabis company, Jazz is known for Epidiolex, an FDA-approved drug derived from cannabis used to treat certain severe forms of epilepsy. Jazz Pharmaceuticals had a strong 2025, with total revenues reaching $4.3 billion, a 5% increase year-over-year. Epidiolex alone contributed $1.1 billion in revenue in 2025, growing 9% year-over-year. The company continued its impressive performance into 2026, reporting first-quarter revenue of $1.07 billion, a 19% increase year-over-year, significantly beating analyst estimates. Their adjusted EPS for Q1 2026 was $6.34, also well above expectations. Jazz Pharmaceuticals has provided 2026 total revenue guidance in the range of $4.25 billion to $4.50 billion. The recent federal rescheduling of FDA-approved cannabis products to Schedule III directly benefits companies like Jazz, streamlining their operations and potentially opening new avenues for research and development.

Another biotech name to watch, albeit with higher risk, is Corbus Pharmaceuticals (CRBP). This clinical-stage biotech company is focused on developing endocannabinoid-related therapies for conditions like cancer and metabolic diseases. While Corbus has no approved products yet and operates with substantial research and development (R&D) expenses, its pipeline includes promising candidates like CRB-701 for solid tumors and CRB-913 for obesity. In Q3 2025, the company reported a net loss of $23.3 million with no revenue, but management believes their cash reserves, bolstered by a $75 million public offering, should extend into 2028. Corbus is a speculative play, with its future heavily tied to successful clinical trial readouts.

While the cannabis sector is brimming with potential, especially with the recent federal rescheduling, it's crucial to understand the risks involved. This industry is still heavily influenced by regulatory changes, which can be both a blessing and a curse.

Regulatory Uncertainty: The ongoing administrative hearing regarding the broader rescheduling of marijuana to Schedule III, expected to conclude by mid-July 2026, is a major event. The outcome will determine the extent of federal reform beyond medical cannabis. There are also potential legal challenges to the current rescheduling order, which could introduce further uncertainty. Investors need to stay informed about these developments, as they can significantly impact market sentiment and company operations.

Market Volatility and Competition: The cannabis market, particularly for MSOs, can be highly volatile. Price compression in various state markets continues to be a challenge, impacting profitability even for established players. Competition is also fierce, with companies constantly vying for market share and consumer loyalty. While some companies like Green Thumb Industries have shown strong cash flow, others, like Innovative Industrial Properties, have faced revenue declines due to tenant defaults.

Economic Headwinds: Broader economic conditions can also affect consumer spending on cannabis products and the capital available for industry expansion. Companies with strong balance sheets and diversified revenue streams, like Scotts Miracle-Gro with its core consumer business, tend to be more resilient during such times.

As a retail investor, always remember that investing in individual cannabis stocks carries higher risk compared to more established industries. Diversification, thorough research into each company's financials, and a clear understanding of the evolving regulatory landscape are your best friends in this exciting, but complex, market.